FDA Staff Propose Against 503A Listing for BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon & DSIP

FDA staff have now put their cards on the table. In briefing documents and presentations for the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting, the agency proposed that all seven peptides on the agenda, free base and acetate forms, NOT be placed on the Section 503A Bulks List. That is the clearest public signal yet of where agency reviewers stand on BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon, and DSIP/Emideltide (DSIP).

This is a follow-up to our pre-meeting PCAC preview. The distinction that matters: these are FDA staff proposals, not a final agency rule, and not the same thing as a published committee vote tally. As of this writing, FDA has posted the meeting materials and staff presentations; we have not yet seen an official public roll-call summary of the committee votes on fda.gov.

TL;DR

• What: FDA staff proposed that 14 bulk-drug-substance forms (seven peptides × free base + acetate) NOT be included on the 503A Bulks List.
• When: Materials prepared for the July 23-24, 2026 PCAC meeting at FDA White Oak, Silver Spring, MD.
• Which compounds: Day 1: BPC-157, KPV, TB-500, MOTS-c. Day 2: Emideltide (DSIP), Epitalon, Semax.
• Key wrinkle: Nominations for these substances were withdrawn, and FDA says it is evaluating them at its discretion anyway.
• The caveat: A staff proposal is not a final rule, not an FDA drug ban, and not the same as an FDA-approved vs. banned binary. PCAC recommendations are non-binding; listing changes still require rulemaking.

What FDA actually proposed

Across the introduction briefing package and the day-of staff presentations, the language is consistent and blunt. For each substance pair, FDA states that it is proposing the free base and the acetate not be included on the 503A Bulks List. The pattern repeats for every peptide on the agenda:

• BPC-157 (free base and acetate): proposed not included.
• KPV (free base and acetate): proposed not included.
• TB-500 (free base and acetate): proposed not included.
• MOTS-c (free base and acetate): proposed not included.
• Emideltide / DSIP (free base and acetate): proposed not included.
• Epitalon (free base and acetate): proposed not included.
• Semax (free base and acetate): proposed not included.

The committee was asked to vote separately on each form (14 vote questions total), for example: “Should BPC-157 (free base) be placed on the list?” and “Should BPC-157 acetate be placed on the list?” That free-base-vs-acetate split matters legally: FDA treats each form as a distinct bulk drug substance.

Why FDA says the balance weighs against listing

FDA evaluates 503A bulk nominations with a four-part balancing test established in its February 2019 final rule:

1. Physical and chemical characterization
2. Safety issues raised by use in compounded products
3. Available evidence of effectiveness, or lack of effectiveness
4. Historical use in compounded products

In the staff materials, recurring conclusions show up substance after substance:

• The peptides are generally described as not well-characterized from a physical/chemical standpoint (naming inconsistencies, incomplete impurity/aggregate/microbial/endotoxin data).
• Immunogenicity risk is flagged for injectable and nasal routes.
• Clinical effectiveness evidence for the nominated uses is described as thin or absent, while FDA-approved alternatives already exist for those conditions.
• Historical compounding-use data is often called too limited to rely on.

A few substance-specific notes from the staff packages (not independent medical conclusions of ours):

• BPC-157 was evaluated for ulcerative colitis. Staff cite limited clinical effectiveness data for that use and insufficient clinical safety characterization, including immunogenicity concerns.
• Epitalon materials raise a mechanistic cancer concern tied to telomere-lengthening biology: staff note that continuous chronic exposure could, in theory, help cells evade senescence.
• Semax materials discuss limited characterization plus safety signals staff associated with real-world exposure reports and pharmacologic concerns.
• TB-500 and MOTS-c are discussed in the context of wound healing / metabolic-bone uses respectively, again with “not well-characterized” and alternative-therapy framing.

If any of these names are new, plain-English definitions live in our peptide glossary.

Withdrawn nominations, evaluated anyway

One of the most important procedural facts in the package: the nominations were withdrawn, and FDA is still evaluating the substances at its discretion.

That is not a technicality. It means the July meeting was not simply “sponsors asked, committee rubber-stamps.” FDA chose to bring these bulk substances forward on its own initiative after nominators pulled back. Staff also note they still considered information submitted in the withdrawn nominations as part of the evaluation.

What this does, and does not, mean

It is easy to flatten this into “FDA banned BPC-157” or “compounding is over.” Neither is an accurate read of the documents.

What the staff proposals would support, if carried through later rulemaking:

• A decision not to place these substances on the affirmative 503A Bulks List.
• Continued absence of the cleanest statutory pathway for traditional 503A pharmacies to compound them from bulk (these substances generally lack a USP/NF monograph and are not components of FDA-approved drugs).

What the staff proposals are NOT:

• Not an FDA approval decision. Compounded drugs are not FDA-approved for safety and efficacy even when a bulk substance is listable.
• Not automatically a criminal ban on every research, clinical-trial, or foreign-regulated context.
• Not a final rule. FDA’s own briefing intro states the agency does not intend to issue a final determination until advisory-committee input is considered and reviews are finalized, and that the final determination may be affected by issues not discussed at the meeting.
• Not the same as a published PCAC vote tally. Committee votes are recommendations; FDA decides; list changes move through notice-and-comment rulemaking.

For the broader architecture of 503A vs. 503B, category policy, and why the Bulks List matters, see our explainer on the compounded peptides 503A/503B landscape in 2026.

Realistic timeline

Even if the committee ultimately aligned with staff, do not expect pharmacy shelves to change the same week. A PCAC recommendation feeds FDA’s administrative process. Changes to the 503A Bulks List are made through regulations, not press-conference vibes. Historically that means months of additional review and formal rulemaking, not an overnight on/off switch.

Near term, the practical signals to watch are:

1. Any official PCAC vote summary / meeting minutes FDA posts.
2. Whether FDA proceeds to a proposed rule covering these substances.
3. How state boards and 503A/503B pharmacies interpret enforcement risk in the meantime.

What it means for patients and practitioners

For patients, nothing in the staff proposal package instantly rewrites an existing clinician relationship. It does raise the odds that the “clear compounding pathway” many people hoped this meeting would unlock is not the path FDA reviewers currently favor. If you are looking for a licensed clinician rather than gray-market sourcing, start with our provider directory.

For practitioners, the nominated uses FDA chose to evaluate remain a tell. BPC-157 was not reviewed as a catch-all “healing peptide”; it was reviewed for ulcerative colitis. Marketing claims and the agency’s review frame are not the same thing. Track the committee reasoning and any eventual rule text, not just social-media scorecards.

For the market, a staff-wide “do not list” posture increases pressure on quality, documentation, and channel discipline. Whatever the final regulatory destination, COAs, sourcing transparency, and avoiding overclaim remain the parts buyers and clinics can control now.

The honest bottom line

The July 2026 PCAC materials are a big deal because they replace rumor with a primary-source staff position: FDA reviewers proposed against 503A Bulks List inclusion for every peptide on the agenda. That is newsworthy. It is also incomplete until vote tallies, committee discussion nuance, and FDA’s post-meeting rulemaking posture are public.

Read it as a strong directional signal from agency staff, not as a finished law, and not as medical advice about any individual therapy.

Not medical advice. This article is educational and informational only. Nothing here is a prescription, dosing recommendation, or individualized medical guidance. Regulatory status does not equal safety or efficacy for any person. Always consult a licensed healthcare provider.

We’ll update this story when FDA posts official committee vote results, meeting minutes, or any proposed rule affecting these substances. Check the dateline above for the latest revision.